<DOC>
	<DOCNO>NCT02887365</DOCNO>
	<brief_summary>Investigators would like assess efficacy safety tegafur-uracil patient stage II MSI-L MSS colon cancer metronomic set one year .</brief_summary>
	<brief_title>A Phase II Study Tegafur-Uracil Maintenance Chemotherapy Patients With Stage II Colon Cancer</brief_title>
	<detailed_description>Approximately 15 % case colon cancer associate type inherit susceptibility call defective DNA mismatch repair ( MMR ) , frequently measure either presence microsatellite instability ( MSI ) test loss protein product gene involve DNA MMR ( MLH1 , MSH2 , MSH6 PMS2 ) . Tumors classify accord percentage abnormal microsatellite region present : &gt; 30-40 % high-level MSI ( MSI-H ) , &lt; 30-40 % low-level MSI ( MSI-L ) abnormalities microsatellite stable ( MSS ) . In condition MSI presence , evidence show MSI marker favorable survival outcome predictor decrease benefit adjuvant therapy 5-FU patient stage II disease . MSI status use clinic prognostic tool identify subgroup stage II patient improved prognosis . Patients MSI-H tumor suggest adjuvant chemotherapy patient MSI-L MSS tumor benefit adjuvant chemotherapy . oral tegafur-uracil adjuvant chemotherapy patient Dukes ' stage B2 C2 colon cancer could good alternative infusional 5-FU . Current evidence suggest adjuvant 5-FU-based therapy could improve survival outcome patient stage II MSI-L MSS colon cancer , patient MSI-H colon cancer . Thus , oral tegafur-uracil consider similar efficacy 5-FU population .</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Microsatellite Instability</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>Inclusion Criteria To eligible inclusion , subject must fulfill follow criterion : 1. pathologically confirm adenocarcinoma colon stage II disease ; 2. complete resection primary tumor ; 3. detection low level microsatellite instability ( MSIL ) microsatellite stable ( MSS ) resect tumor sample ; 4. prior chemotherapy radiotherapy colon cancer ; 5 . ECOG performance status 0 1 ; 6. age 20 year old ; 7. able start study treatment within 8 week surgery ; 8. able understand willingness sign write informed consent document . Exclusion Criteria Subjects fulfill follow criterion exclude trial : 1 . Severe postoperative complication ; 2. inadequate hematopoietic function define : 1. hemoglobin &lt; 9 g/dL ; 2. absolute neutrophil count ( ANC ) â‰¤ 1,500/mm3 ; 3. platelet count &lt; 100,000/mm3 ; 3. inadequate hepatic function define : 1. total bilirubin &gt; 2 time upper limit normal ( ULN ) ; 2. hepatic transaminase ( ALT AST ) &gt; 2.5 x ULN ; 4. inadequate renal function define : a.creatinine &gt; 1.5 x ULN ; 5. significant medical condition contraindicate study medication render patient high risk treatment complication base investigator 's discretion ; 6. malignancy within past 5 year except adequately treat basal squamous cell skin cancer cervical cancer situ ; 7. participation another clinical trial investigational drug within 30 day prior entry ; 8. pregnant woman nurse mother , positive pregnancy test woman childbearing potential . Patients childbearing potential effective contraception patient partner study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>colon cancer</keyword>
	<keyword>MSI-L</keyword>
	<keyword>MSS</keyword>
	<keyword>Tegafur-Uracil</keyword>
	<keyword>Low-Level Microsatellite-Instability</keyword>
</DOC>